All | EFI | TNI | p-value | Stage I/II | Stage III | p-value | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
# patients | 107 | 48 | 59 | 86 | 21 | |||||||
Age | <0.001 | <0.001 | ||||||||||
median/range [years] | 57 | 26 - 83 | 66 | 37 - 83 | 51 | 26 - 74 | 61 | 27 – 83 | 51 | 26 - 68 | ||
≥60 years | 48 | 45% | 35 | 73% | 13 | 22% | 45 | 52% | 3 | 14% | ||
Sex [male] | 59 | 57% | 26 | 55% | 33 | 56% | NS | 49 | 57% | 10 | 48% | |
Karnofsky Performance status | <0.001 | NS | ||||||||||
median/range | 90 | 50 - 100 | 90 | 50 - 100 | 100 | 80 - 100 | 90 | 50 – 100 | 90 | 70 – 100 | ||
B-Symptoms | 1 | 1% | 0 | 0% | 1 | 2% | NS | 0 | 0% | 1 | 5% | NS |
LDH | NS | 0.03 | ||||||||||
Elevated | 16 | 15% | 9 | 19% | 7 | 12% | 8 | 9% | 8 | 38% | ||
Normal | 63 | 59% | 29 | 60% | 34 | 58% | 55 | 64% | 8 | 24% | ||
unknown | 28 | 26% | 10 | 21% | 18 | 30% | 23 | 27% | 5 | 38% | ||
Ann Arbor stage | 0.04 | |||||||||||
I | 50 | 47% | 27 | 56% | 23 | 39.0% | ||||||
II | 36 | 34% | 18 | 38% | 18 | 30.5% | ||||||
III | 21 | 20% | 3 | 6% | 18 | 30.5% | ||||||
Bulk ≥7.5 cm | 5 | 5% | 2 | 4% | 3 | 5% | NS | 3 | 3% | 2 | 9% | NS |
Radiotherapy dose median/range [Gy] | 38 | 25 - 50 | 38 | 27 - 50 | 37 | 25 - 46 | NS | 37 | 25 - 50 | 37 | 29 - 46 | NS |